Item 7.01 Regulation FD Disclosure.

On January 8, 2023, Viridian Therapeutics, Inc. issued a press release announcing, and made available a presentation regarding, positive topline data from its Phase 1/2 trial of VRDN-001 in patients who suffer from thyroid eye disease. The press release and data presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, which are furnished under Item 7.01 of this Current Report on Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.



Exhibit
Number       Exhibit Description

99.1           Press release regarding topline data, dated January 8, 2023

99.2           Viridian Therapeutics, Inc. Topline Data Presentation, dated January
             2023

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses